Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Aurora Cannabis

Aphria

Canopy Growth

Cronos Group

Good news for the cannabis industry is standing out on a calm market day.

Why Pot Stocks Are Soaring Again in Tuesday's Stock Market

Tilray stock soared after an agreement with Grow Pharma to import and distribute its medical cannabis products in the United Kingdom.

Tilray shares surge nearly 40% on deal to import and distribute medical cannabis in the UK

Tilray Inc. (NASDAQ: TLRY) shares jumped on Tuesday after the company announced that it would be expanding its operations across the pond.

Tilray Expands Cannabis Empire Across the Pond

SNDL Inc.

Cannabis stocks like SNDL, CGC and TLRY stock are on the move Monday after Tilray announced a medical marijuana distribution deal. The post Cannabis Stocks: Why TLRY, CGC, APHA, ACB and SNDL Are Climbing Today appeared first on InvestorPlace.

Cannabis Stocks: Why TLRY, CGC, APHA, ACB and SNDL Are Climbing Today

Tilray stock soared by more than 20% early Tuesday after the company announced a deal with Grow Pharma to import and distribute its medical cannabis in the UK. Patients in the UK will be able to obtain Tilray's cannabis through prescriptions from the country's National Health Service or from private practices.

Tilray jumps 20% on deal with Grow Pharma to distribute medical cannabis in the UK (TLRY)

Tilray stock headed for its second straight day of explosive gains Tuesday after the pot grower announced a deal to ship medical marijuana to Britain. The Canadian company's shares surged about 20 percent in premarket trading to $36.25 as of 8:02 a.m.

Tilray stock surges for second day after UK cannabis deal

Zynga

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Here's Why Tilray, Aphria, Zynga Are Moving

GrowGeneration Corp

The monster combination of Aphria and Tilray is a loadstone that has sparked a faith-based move by investors into the cannabis space over recent weeks. That has been helped by continued aggressive speculator involvement in the equities market more generally.

Pot Stock Outperformance and How to Play It (OTC US: GRWG) (OTC US: MEDH) (NASDAQ: TLRY)

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has established an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom (UK). This agreement allows Tilray to provide authorized UK patients in need with a locally maintained supply of medical cannabis solutions. Tilray expects to have a range of GMP-certified, medica

Tilray® Announces Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the United Kingdom

Cannabis companies have seen their share prices rise significantly this year as U.S. lawmakers look set to tackle federal marijuana reform measures. What Happened: Shares of Tilray Inc. (NASDAQ:TLRY) have gained over 250% since the start of January.

Is Tilray Set For Another Short Squeeze?

HEXO Corp

OrganiGram Holdings Inc.

The U.S. Cold War against cannabis is rapidly thawing.

Why a Slew of Marijuana Stocks Blasted Higher Today

Since the merger was announced last December, Tilray shares have detached from the merger price and are trading at a ~30% premium. Merger arbitrage is best played through a paired trade (long Aphria and short Tilray); market prices indicate borrowing costs of shorting Tilray is much higher than the ~30% merger discount.

Tilray/Aphria: The 30% Merger Arbitrage Is Tough To Play

Amplify Alternative Harvest ETF

With Democrats in both chambers of Congress and a Biden White House, federal legalization may be close to reality.

Op-ed: Cannabis investors are about to ride a legislative tailwind in Washington

The pot producer was swept along by a tide of good news.

Why Tilray Surged 119.1% in January

Let's take a look at a couple of cannabis stocks that are off to a hot start in February.

2 Cannabis Stocks off to a Hot Start in February

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech ("Worldpharma"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the

Tilray® Exports First Shipment of Medical Cannabis to Spain

Hint: it has little to do with weed production.

1 Crucial Factor for Cannabis Investors to Look At

GW Pharmaceuticals

Cannabis stocks rallied anew on Wednesday, spurred on by news of a $7 billion deal for the first company to win U.S. regulatory approval for a cannabis-based drug, a move that's expected to boost investor interest in the plant and its medical benefits.

Cannabis Watch: Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits

Some pot stocks are jumping double digits after recent comments from Democratic lawmakers.

Why Tilray, Aphria, OrganiGram, and Aurora Cannabis Rose Today

Shares of Tilray climbed as much as 22% Wednesday, extending the stock's rally to the second day on the back of encouraging developments out of Washington, DC, earlier this week.  Tilray, a pharmaceutical and cannabis company headquartered in Toronto, saw its stock price touch the highest level seen in a year, hitting $28.82 at intraday highs.

Tilray stock extends rally as Democrat lawmakers promise to push marijuana reforms

Jazz Pharmaceuticals

In a quiet market, marijuana companies stood out.

Pot Stocks Are Wednesday's Big Stock Market Winners. Will They Disappoint Shareholders in the End?

The shares of several cannabis companies are trading higher on Wednesday following the announcement of the Jazz Pharma deal for GW Pharma . GW Pharma was one of the first pharma companies to use cannabinoids for medical therapy.

Why Aurora Cannabis, Cronos And Tilray Are Trading Higher Today

Cannabis stocks are heading higher Wednesday as investors hope for national legalization of the drug following comments from Chuck Schumer. The post Cannabis Stocks: Why TLRY, ACB, CGC, APHA and SNDL Stocks Are Surging Wednesday appeared first on InvestorPlace.

Cannabis Stocks: Why TLRY, ACB, CGC, APHA and SNDL Stocks Are Surging Wednesday

Alibaba

Here's why shares of Snap, Alibaba and cannabis companies are moving. Shares of Snap Inc (NYSE:SNAP) are trading higher, potentially in anticipation of the company's Thursday earnings report.

Here's Why Snap, Alibaba, Tilray, Aurora And Aphria Are Moving

High-profile senators are determined to get the legislative ball rolling on pot reform.

News for Tilray Brands Stock (TLRY)